Co-prescription of acid suppressive therapy, together with advances in small bowel imaging
techniques, have shifted the burden of NSAID-related toxicity from gastro-duodenal to more …

Introduction: Anti-tumor necrosis factor (TNF) dose intensification represents an effective
method of overcoming secondary loss of response (LOR); however, a subset of patients may …

Abstract Background and Aims Preliminary data regarding the effectiveness of tofacitinib in
acute severe ulcerative colitis [ASUC] have been presented in two previous case series. We …

Background & Aims Higher anti-tumor necrosis factor-α (TNF) drug levels are associated
with improved clinical healing of Crohn's perianal fistulas. It is unclear whether this leads to …

Background The GEMINI trials established the efficacy of vedolizumab in moderate-to-
severe inflammatory bowel disease (IBD) and demonstrated a favorable safety profile …

A treat-to-target (T2T) approach applies the principles of early intervention and tight disease
control to optimise long-term outcomes in Crohn's disease. The Selecting Therapeutic …

BACKGROUND Vedolizumab (VDZ), a humanised monoclonal antibody that selectively
inhibits alpha4-beta7 integrins is approved for use in adult moderate to severe ulcerative …

Objective To examine whether non‐medical switching of patients with inflammatory bowel
disease (IBD) from originator infliximab to a biosimilar (CT‐P13, Inflectra) is safe and …

Abstract Background and Aims The optimal duration of dose-intensified therapy following
secondary loss of response [LOR] to anti-tumour necrosis factor [TNF] therapy remains …

Background Despite growing awareness of the nocebo effect, few studies have evaluated
the nocebo effect using combined assessment of patient-reported outcome measures …